We are live on ! Find out more
ADXN

Addex Therapeutics
ADXN

10 hedge funds and large institutions have $1.21M invested in Addex Therapeutics in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

100% more funds holding

Funds holding: 5 → 10 (+5)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

76.64% more ownership

Funds ownership: 20.33% → 96.96% (+77%)

18% less capital invested

Capital invested by funds: $1.48M → $1.21M (-$268K)

Holders
10
Holders Change
+5
Holders Change %
+100%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
+$5.27M
2
AC
Armistice Capital
New York
+$74.9K
3
Renaissance Technologies
Renaissance Technologies
New York
+$33K
4
FIA
FNY Investment Advisers
New York
+$25.2K
5
Millennium Management
Millennium Management
New York
+$22.3K

Top Sellers

Rank Fund Capital Flow
1
OMC
Old Mission Capital
Illinois
-$36K
2
UBS Group
UBS Group
Switzerland
-$1.03K

ADXN Hedge Fund Activity: Q3 2022 in Review

10 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q3 2022, worth a combined $1.21M — down 18% from $1.48M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new ADXN positions and 1 closed out — a net gain of 5 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was NEA Management Company, adding an estimated $5.27M. The largest seller was Old Mission Capital, exiting entirely with an estimated $36K sold.

  • 10 institutional investors held Addex Therapeutics (ADXN) as of Q3 2022, up from 5 in Q2 2022.
  • Funds reported $1.21M of Addex Therapeutics stock for Q3 2022, down 18% quarter-over-quarter.
  • 6 funds opened new Addex Therapeutics positions in Q3 2022 and 1 closed out, a net change of +5 holders.
  • The largest Addex Therapeutics buyer in Q3 2022 was NEA Management Company, an estimated $5.27M added.
  • The largest Addex Therapeutics seller in Q3 2022 was Old Mission Capital, an estimated $36K sold.

Based on aggregated 13F filings for Q3 2022.